|
Volumn 202, Issue 1, 2001, Pages 38-43
|
Pharmacoeconomic evaluation of calcipotriol (Daivonex®/Dovonex®) and UVB phototherapy in the treatment of psoriasis: A Markov model for the Netherlands
|
Author keywords
Calcipotriol; Cost; Daivonex ; Dovonex ; Markov model; Pharmacoeconomic evaluation; Psoriasis; Ultraviolet B
|
Indexed keywords
CALCIPOTRIOL;
CORTICOSTEROID;
DITHRANOL;
EMOLLIENT AGENT;
TAR;
ARTICLE;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
COST CONTROL;
COST EFFECTIVENESS ANALYSIS;
DRUG COST;
HUMAN;
LIGHT DAMAGE;
MAINTENANCE THERAPY;
MAJOR CLINICAL STUDY;
NETHERLANDS;
PHOTOCHEMOTHERAPY;
PRIORITY JOURNAL;
PSORIASIS;
PUVA;
SIMULATION;
TREATMENT OUTCOME;
TREATMENT PLANNING;
ULTRAVIOLET B RADIATION;
CALCITRIOL;
COMBINED MODALITY THERAPY;
COST-BENEFIT ANALYSIS;
ECONOMICS, PHARMACEUTICAL;
HUMANS;
MARKOV CHAINS;
NETHERLANDS;
PSORIASIS;
SKIN;
TIME FACTORS;
TREATMENT OUTCOME;
ULTRAVIOLET THERAPY;
|
EID: 0035105805
PISSN: 10188665
EISSN: None
Source Type: Journal
DOI: 10.1159/000051583 Document Type: Article |
Times cited : (15)
|
References (16)
|